Literature DB >> 35132576

ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.

Dinesh Babu Somasundaram1, Sheeja Aravindan2, Nandita Gupta3, Zhongxin Yu4, Ashley Baker5, Natarajan Aravindan6,7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35132576     DOI： 10.1007/s12519-022-00517-5

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


× No keyword cloud information.
  49 in total

1.  New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.

Authors:  Kristina A Cole; John M Maris
Journal:  Clin Cancer Res       Date:  2012-03-16       Impact factor: 12.531

2.  Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.

Authors:  Thorsten Simon; Frank Berthold; Arndt Borkhardt; Bernhard Kremens; Boris De Carolis; Barbara Hero
Journal:  Pediatr Blood Cancer       Date:  2010-12-09       Impact factor: 3.167

3.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Authors:  Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

Review 4.  Neuroblastoma: biological insights into a clinical enigma.

Authors:  Garrett M Brodeur
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

5.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

6.  Factors influencing survival in children with recurrent neuroblastoma.

Authors:  Loretta Lau; Derek Tai; Sheila Weitzman; Ronald Grant; Sylvain Baruchel; David Malkin
Journal:  J Pediatr Hematol Oncol       Date:  2004-04       Impact factor: 1.289

7.  Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

Authors:  Alberto Garaventa; Stefano Parodi; Bruno De Bernardi; Daniela Dau; Carla Manzitti; Massimo Conte; Fiorina Casale; Elisabetta Viscardi; Maurizio Bianchi; Paolo D'Angelo; Giulio Andrea Zanazzo; Roberto Luksch; Claudio Favre; Angela Tamburini; Riccardo Haupt
Journal:  Eur J Cancer       Date:  2009-07-16       Impact factor: 9.162

Review 8.  Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy.

Authors:  Daniel A Morgenstern; Sylvain Baruchel; Meredith S Irwin
Journal:  J Pediatr Hematol Oncol       Date:  2013-07       Impact factor: 1.289

9.  Disease control intervals in high-risk neuroblastoma.

Authors:  Victor M Santana; Wayne L Furman; Lisa M McGregor; Catherine A Billups
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

10.  Cancer stem cells in neuroblastoma therapy resistance.

Authors:  Natarajan Aravindan; Drishti Jain; Dinesh Babu Somasundaram; Terence S Herman; Sheeja Aravindan
Journal:  Cancer Drug Resist       Date:  2019-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.